[1] SMYTH E C,NILSSON M,GRBBSCH H I,et al.Gastric cancer[J].Lancet,2020,396(10251):635-648.
[2] ZHAO B,MEI D,LV W,et al.Clinicopathologic features,survival outcome,and prognostic factors in gastric cancer patients 18-40 years of age[J].J Adolesc Young Adult Oncol,2020,9(4):514-521.
[3] ISOBE T,HASHIMOTO K,KIZAKI J,et al.Characteristics and prognosis of gastric cancer in young patients[J].Oncol Rep,2013,30(1):43-49.
[4] GUAN W L,YUAN L P,YAN X L,et al.More attention should be paid to adult gastric cancer patients younger than 35 years old:extremely poor prognosis was found[J].J Cancer,2019,10(2):472-478.
[5] TAKATSU Y,HIKI N,NUNOBE S,et al.Clinicopathological features of gastric cancer in young patients[J].Gastric Cancer,2016,19(2):472-478.
[6] DE B,RHOME R,JAIRAM V,et al.Gastric adenocarcinoma in young adult patients:patterns of care and survival in the United States[J].Gastric Cancer,2018,21(6):889-899.
[7] CHENG L,CHEN S,WU W,et al.Gastric cancer in young patients:a separate entity with aggressive features and poor prognosis[J].J Cancer Res Clin Oncol,2020,146(11):2937-2947.
[8] WESOIOWSKA M,PAWLIK P,JAGODZINSKI P P.The clinicopathologic significance of estrogen receptors in human gastric carcinoma[J].Biomed Pharmacother,2016,83:314-322.
[9] ALLEMANI C,MATSUDA T,DI CARLO V,et al.Global surveillance of trends in cancer survival 2000-14(CONCORD-3):analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries[J].Lancet,2018,391(10125):1023-1075.
[10] KIM K H,KIM Y M,KIM M C,et al.Analysis of prognostic factors and outcomes of gastric cancer in younger patients:a case control study using propensity score methods[J].World J Gastroenterol,2014,20(12):3369-3375.
[11] CHUNG H W,NOH S H,LIM J B.Analysis of demographic characteristics in 3242 young age gastric cancer patients in Korea[J].World J Gastroenterol,2010,16(2):256-263.
[12] RAMOS M F K P,PEREIRA M A,SAGAE V M T,et al.Gastric cancer in young adults:a worse prognosis group?[J].Rev Col Bras Cir,2019,46(4):e20192256.
[13] CHOI Y,KIM N,KIM K W,et al.Sex-based differences in histology,staging,and prognosis among 2983 gastric cancer surgery patients[J].World J Gastroenterol,2022,28(9):933-947.
[14] LOBO S,BENUSIGLIO P R,COULET F,et al.Cancer predisposition and germline CTNNA1 variants[J].Eur J Med Genet,2021,64(10):104316.
[15] KIM D Y,RYU S Y,KIM Y J,et al.Clinicopathological characteristics of gastric carcinoma in young patients[J].Langenbecks Arch Surg,2003,388(4):245-249.
[16] SONG M,KANG D,YANG J J,et al.Age and sex interactions in gastric cancer incidence and mortality trends in Korea[J].Gastric Cancer,2015,18(3):580-589.
[17] AMIEVA M,PEEK R M J R.Pathobiology of Helicobacter pylori-induced gastric cancer[J].Gastroenterology,2016,150(1):64-78.
[18] PARK Y,KI M.Poulation attributable fraction of Helicobacter pylori infection-related gastric cancer in Korea:a meta-analysis[J].Cancer Res Treat,2021,53(3):744-753.
[19] TATEMICHI M,SASAZUKI S,INOUE M,et al.Different etiological role of Helicobacter pylori(Hp) infection in carcinogenesis between differentiated and undifferentiated gastric cancers:a nested case-control study using IgG titer against Hp surface antigen[J].Acta Oncol,2008,47(3):360-365.
[20] HIRAHASHI M,YAO T,MATSUMOTO T,et al.Intramucosal gastric adenocarcinoma of poorly differentiated type in the young is characterized by Helicobacter pylori infection and antral lymphoid hyperplasia[J].Mod Pathol,2007,20(1):29-34.
[21] BURUCOA C,AXON A.Epidemiology of Helicobacter pylori infection[J/OL].Helicobacter,2017,22 Suppl 1.doi:10.1111/hel.12403.
[22] QU X,ZHAO X,LIU Y,et al.The clinicopathological characteristics of early-onset gastric cancer and its evolutionary trends:a retrospective study[J].Am J Cancer Res,2022,12(6):2757-2769.
[23] MAN J,NI Y,YANG X,et al.Healthy lifestyle factors,cancer family history,and gastric cancer risk:a population-based case-control study in China[J].Front Nutr,2021,8:774530.
[24] BEVAN S,HOULSTON R S.Genetic predisposition to gastric cancer[J].QJM,1999,92(1):5-10.
[25] SETIA N,WANG C X,LAGER A,et al.Morphologic and molecular analysis of early-onset gastric cancer[J].Cancer,2020,127(1):103-114.
[26] CORSO G,PEDRAZZANI C,PINHEIRO H,et al.E-cadherin genetic screening and clinico-pathologic characteristics of early onset gastric cancer[J].Eur J Cancer,2011,47(4):631-639.
[27] GULLO I,DEVEEZAS V,BAPTISTA M,et al.Phenotypic heterogeneity of hereditary diffuse gastric cancer:report of a family with early-onset disease[J].Gastrointest Endosc,2018,87(6):1566-1575.
[28] BARNOUD T,PARRIS J L D,MURPHY M E.Common genetic variants in the TP53 pathway and their impact on cancer[J].J Mol Cell Biol,2019,11(7):578-585.
[29] ZHOU F,XU Y,SHI J,et al.Expression profile of E-cadherin,estrogen receptors,and P53 in early-onset gastric cancers[J].Cancer Med,2016,5(12):3403-3411.
[30] MILNE A N,CARVALHO R,MORSINK F M,et al.Early-onset gastric cancers have a different molecular expression profile than conventional gastric cancers[J].Mod Pathol,2006,19(4):564-572.
[31] GUINDALINI R S C,CORMEDI M C V,MAISTRO S,et al.Frequency of CDH1 germline variants and contribution of dietary habits in early age onset gastric cancer patients in Brazil[J].Gastric Cancer,2019,22(5):920-931.
[32] WU-WILLIAMS A H,YU M C,MACK T M.Life-style,workplace,and stomach cancer by subsite in young men of Los Angeles County[J].Cancer Res,1990,50(9):2569-2576.
[33] JANG J,LEE S,KO K P,et al.Association between body mass index and risk of gastric cancer by anatomic and histologic subtypes in over 500,000 East and Southeast Asian cohort participants[J].Cancer Epidemiol Biomarkers Prev,2022,31(9):1727-1734.
[34] JUO Y Y,GIBBONS M A M,DUTSON E,et al.Obesity is associated with early onset of gastrointestinal cancers in California[J].J Obes,2018,2018:7014073.
[35] 赫捷,陈万青,李兆申,等.中国胃癌筛查与早诊早治指南(2022,北京)[J].中国肿瘤,2022,31(7):488-527.
[36] FENG F,TIAN Y,XU G,et al.Diagnostic and prognostic value of CEA,CA19-9,AFP and CA125 for early gastric cancer[J].BMC Cancer,2017,17(1):737.
[37] SJOMINA O,PAVLOVA J,DAUGULE I,et al.Pepsinogen test for the evaluation of precancerous changes in gastric mucosa:a population-based study[J].J Gastrointestin Liver Dis,2018,27(1):11-17.
[38] BEGUM A,BATEN M A,BEGUM Z,et al.Role of serum pepsinogen I and II ratio in screening of gastric carcinoma[J].Mymensingh Med J,2017,26(3):628-634.
[39] 王颖,刘申香,童建东.Ki-67抗原和P53蛋白在胃黏液腺癌组织中的表达及预后分析[J].现代医学,2020,48(11):1413-1419.
[40] FARIAS C B,LIMA R C,LIMA L O,et al.Stimulation of proliferation of U138-MG glioblastoma cells by gastrin-releasing peptide in combination with agents that enhance cAMP signaling[J].Oncology,2008,75(1-2):27-31.
[41] BORNSCHEIN J,SELGRAD M,WEX T,et al.Serological assessment of gastric mucosal atrophy in gastric cancer[J].BMC Gastroenterol,2012,12:10.
[42] 张力,汤玮,岳芙蓉,等.血清PG、G-17、CDH-17在胃癌中的表达及其诊断意义[J].实用癌症杂志,2020,35(8):1258-1261.
[43] KIKUCHI R,ABE Y,IIJIMA K,et al.Low serum levels of pepsinogen and gastrin 17 are predictive of extensive gastric atrophy with high-risk of early gastric cancer[J].Tohoku J Exp Med,2011,223(1):35-44.
[44] RASMUS P I H L,JENSEN R K,POULSEN E C,et al.ITIH4 acts as a protease inhibitor by a novel inhibitory mechanism[J].Sci Adv,2021,7(2):eaba7381.
[45] SUN Y,JIN J,JING H,et al.ITIH4 is a novel serum biomarker for early gastric cancer diagnosis[J].Clin Chim Acta,2021,523:365-373.
[46] GALLETTI G,SUNG M S,VAHDAT L T,et al.Isolation of breast cancer and gastric cancer circulating tumor cells by use of an anti HER2-based microfluidic device[J].Lab Chip,2014,14(1):147-156.
[47] KIM D J,LEE W Y,PARK N W,et al.Drug response of captured BT20 cells and evaluation of circulating tumor cells on a silicon nanowire platform[J].Biosens Bioelectron,2015,67:370-378.
[48] LI T T,LIU H,YU J,et al.Prognostic and predictive blood biomarkers in gastric cancer and the potential application of circulating tumor cells[J].World J Gastroenterol,2018,24(21):2236-2246.
[49] HEITZER E,AUINGER L,SPEICHER M R.Cell-free DNA and apoptosis:how dead cells inform about the living[J]. Trends Mol Med,2020,26(5):519-528.
[50] HUANG Z B,ZHANG H T,YU B,et al.Cell-free DNA as a liquid biopsy for early detection of gastric cancer[J].Oncol Lett,2021,21(1):3.
[51] 胡祥.第6版日本《胃癌治疗指南》拔萃[J].中国实用外科杂志,2021,41(10):1130-1141.
[52] VAN DEN ENDE T,TER VEER E,MACHIELS M,et al.The efficacy and safety of(Neo) adjuvant therapy for gastric cancer:a network meta-analysis[J/OL].Cancers(Basel),2019,11(1).doi:10.3990/cancers11010080.
[53] BANG Y J,VAN CUTSEM E,FEYEREISLOVA A,et al.Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer(ToGA):a phase 3,open-label,randomised controlled trial[J].Lancet,2010,376(9742):687-697.
[54] CHEN Y,BAI B,YING K,et al.Anti-PD-1 combined with targeted therapy:theory and practice in gastric and colorectal cancer[J].Biochim Biophys Acta Rev Cancer,2022,1877(5):188775.
[55] WONG B C,LAM S K,WONG W M,et al.Helicobacter pylori eradication to prevent gastric cancer in a high-risk region of China:a randomized controlled trial[J].JAMA,2004,291(2):187-194.
[56] KIM N.Chemoprevention of gastric cancer by Helicobacter pylori eradication and its underlying mechanism[J].J Gastroenterol Hepatol,2019,34(8):1287-1295.
[57] GAMBLE L A,HELLER T,DAVIS J L.Hereditary diffuse gastric cancer syndrome and the role of CDH1:a review[J].JAMA Surg,2021,156(4):387-392.
[58] CLINTON S K,GIOVANNUCCI E L,HURSTING S D.The World Cancer Research Fund/American Institute for cancer research third expert report on diet,nutrition,physical activity,and cancer:impact and future directions[J].J Nutr,2020,150(4):663-671.
[59] SEO S I,PARK C H,YOU S C,et al.Association between proton pump inhibitor use and gastric cancer:a population-based cohort study using two different types of nationwide databases in Korea[J].Gut,2021,70(11):2066-2075. |
